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Background: The determination of dosing regimens for the treatment of malaria is largely empirical and thus a
better understanding of the pharmacokinetic/pharmacodynamic properties of antimalarial agents is required
to assess the adequacy of current treatment regimens and identify sources of suboptimal dosing that could
select for drug-resistant parasites. Mefloquine is a widely used antimalarial, commonly given in combination
with artesunate.
Patients and methods: Mefloquine pharmacokinetics was assessed in 24 healthy adults and 43 patients with
Plasmodium falciparum malaria administered mefloquine in combination with artesunate. Population pharma-
cokinetic modelling was conducted using NONMEM.
Results: A two-compartment model with a single transit compartment and first-order elimination from the cen-
tral compartment most adequately described mefloquine concentration–time data. The model incorporated
population parameter variability for clearance (CL/F), central volume of distribution (VC/F) and absorption rate
constant (KA) and identified, in addition to body weight, malaria infection as a covariate for VC/F (but not CL/F).
Monte Carlo simulations predict that falciparummalaria infection is associated with a shorter elimination half-life
(407 versus 566 h) and T.MIC (766 versus 893 h).
Conclusions: This is the first known population pharmacokinetic study to show falciparum malaria to influence
mefloquine disposition. Protein binding, anaemia and other factorsmay contribute to differences between healthy
individuals and patients. As VC/F is related to the earlier portion of the concentration–time profiles, which occurs
during acute malaria, and CL/F is more related to the terminal phase during convalescence after treatment, this
may explain why malaria was found to be a covariate for VC/F but not CL/F.
Keywords: PK, pharmacometrics, P. falciparum
Introduction
Malaria is a leading cause of mortality and morbidity in developing
areas of the world, with an estimated 216 million individuals
infected each year, of which 80% are within sub-Saharan Africa
and South America.1 The current WHO recommendation for the
treatment of uncomplicated Plasmodium falciparum malaria is
with artemisinin combination therapy comprising two schizontoci-
dal drugs with independent modes of action, specifically a
rapid-acting artemisinin-derived compound administered with a
more slowly eliminated antimalarial (e.g. mefloquine).2 Artesunate
and mefloquine combination treatments have been shown to
achieve consistently high efficacy rates and reduced malaria mor-
bidity, including in areas of multidrug resistance.3
Mefloquine is an orally administered blood schizontocide, active
against the erythrocytic stages of P. falciparum infection.4 The total
recommended dose of mefloquine, administered in combination
with artesunate for the treatment of malaria infection, is 25 mg/kg
typically given as a split dose over 2 days (15+10 mg/kg) or
24 mg/kg administered over 3 days (8+8+8 mg/kg).4–7 Whilst this
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dose recommendation has been established as efficacious in the
treatment of uncomplicated falciparum malaria in adult patients,
the dose regimen is largely empirical and a better understanding of
the pharmacokinetic and pharmacodynamic properties of meflo-
quine is required to ensure rational use and optimal dosing regimens.
Mefloquine pharmacokinetics is characterized by low apparent
oral clearance, a large apparent volume of distribution and conse-
quently a long terminal half-life; however, considerable interindi-
vidual differences have been reported.4 Given that treatment
efficacy is dependent onmaintenance of parasiticidal blood levels
until all parasites are eliminated from the body, this slow elimin-
ation phase is an important determinant of therapeutic out-
comes.6,8 Research has suggested that mefloquine disposition in
patients with falciparum malaria is different from that in healthy
volunteers, with a substantially reduced half-life (2 weeks com-
pared with 3 weeks).4,9 – 12 Given that traditional (separate)
pharmacokinetic studies in relatively small subsets of participants
are, for the most part, underpowered to ascertain the factors that
contribute to the variability in pharmacokinetics, it is not known
whether these observed differences between patients and
healthy volunteers are due to the presence of malaria infection
or could be accounted for by differences in other factors such as
body weight, gender, etc. In order to investigate this further, a
population pharmacokinetic approach was used to provide esti-
mates ofmefloquine pharmacokinetic parameters and an assess-
ment of the sources of variance in pharmacokinetic parameters in
patients with uncomplicated P. falciparum malaria and healthy
volunteers.
Patients and methods
Pharmacokinetic data were obtained from two clinical studies conducted
in healthy volunteers and patients with uncomplicated P. falciparum mal-
aria.12,13 Non-compartmental pharmacokinetic analysis of the concentra-
tion–time data from these studies has previously been described.12
The clinical studies were conducted at the Hospital for Tropical Disease,
Mahidol University (Bangkok, Thailand) and were reviewed and approved
by the institutional Human Research Ethics Committee. Participants
were fully informed of the study procedures and providedwritten informed
consent prior to study initiation. The studies were conducted in accord-
ance with the study protocols, the Declaration of Helsinki and the princi-
ples of Good Clinical Practice.
Study design
The pharmacokinetics of mefloquine, after administration of one of two
treatment formulations, were to be assessed in 24 healthy adult male
and non-pregnant female volunteers (healthy volunteer study) and 50
male and non-pregnant female patients with slide-proven uncomplicated
P. falciparum malaria (patient study).
In the clinical studies, mefloquine was administered in combination
with artesunate as either a coformulated product (fixed formulation) or
as separate products (non-fixed formulation). The coformulated product
was administered as tablets containing 200 mg of mefloquine and
100 mg of artesunate (FarManguinhos, Rio de Janeiro, Brazil; Batches
#070008 and #069002). The separate products comprised mefloquine
administered as 250 mg tablets (Roche, Basel, Switzerland; Batch
#B1100) and 50 mg artesunate tablets (Guilin Pharmaceutical, Guangxi,
China; Batch #031201).
The healthy volunteer study was conducted according to a rando-
mized, crossover design with a 90 day washout period between treatment
periods. Healthy volunteers were administered a single oral dose of
400 mg of mefloquine as the coformulated product or 500 mg of meflo-
quine as a separate product. In both study periods, blood samples were
collected for analysis of plasmamefloquine concentrations prior to dosing
(0 h) and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, 120, 168, 336,
504, 672, 1008, 1344, 1680 and 2160 h after treatment administration.
The patient study was conducted according to a randomized, parallel
design with patients randomly allocated to receive multiple dosing with
one of the two treatment formulations according to a 1:1 ratio. Patients
received either 400 mg of mefloquine as the coformulated product each
day for 3 days, or 25 mg/kg mefloquine administered as a separate prod-
uct as a spilt dose over 2 days (15 mg/kg+10 mg/kg). For patients admi-
nistered the coformulated product, blood samples were collected prior to
dosing (0 h) and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 (pre-dose #2),
48 (pre-dose #3), 72, 120, 168, 336, 504 and 672 h after administration of
the first dose. For patients administered the separate products, blood sam-
ples were collected prior to dosing (0 h) and at 24 (pre-dose #2), 48, 96,
144, 312, 480 and 648 h after administration of the first dose.
Schematic representations of the study designs are illustrated in
Figure 1.
Biological sample analysis
Plasma samples were analysed for mefloquine concentrations by
Universiti Sains Malaysia (Penang, Malaysia) using validated HPLC-UV
methodology.12,14 The lower limit of quantification of mefloquine was
20 mg/mL, with an accuracy of 98.9% and a coefficient of variation of 8%.
Data for samples returning concentrations below the lower limit of
quantification of the assay were not made available by the analytical
laboratory. These samples and samples for which no values were reported
(i.e. missing) were excluded from the pharmacokinetic dataset.
Population pharmacokinetics
Population pharmacokineticmodellingwas conducted using NONMEMw VI
(ICON Development Solutions, Ellicott City, MD, USA) software with a G77
complier and Wings for NONMEM interface (http://wfn.sourceforge.net).
Full details of the model development protocol and model diagnostics are
available as Supplementary data at JAC Online (http://jac.oxfordjournals.
org/); the pharmacometric methods are briefly described below.
One-, two- and three-compartmentmodels with first-order absorption
and elimination from the central compartment were fitted to mefloquine
plasma concentration–time data. Models with absorption lag time were
screened to account for any time delay between administration and the
beginning of drug absorption. In addition, more complex absorption mod-
els based on a chain of absorption transit compartments were also inves-
tigated.15 The pharmacokinetic models were parameterized (where
appropriate) as clearance (CL/F), volume of distribution of the central com-
partment (VC/F), intercompartmental clearance (CLD/F), volume of distribu-
tion of the peripheral compartment(s) (VP/F), absorption rate constant (KA)
and absorption lag time. The model incorporated population parameter
variability (comprising between-subject variability and between-occasion
variability) and residual unexplained variability (comprising proportional
and additive error).
Once the base structural model had been determined, the contribu-
tions of continuous (age, body weight and baseline parasite count) and
categorical (gender, treatment formulation and presence ofmalaria infec-
tion) covariates to the population parameter variability were assessed
using a forward selection–backward elimination procedure.
Model selection was based on the objective function value (minus
twice the log-likelihood of the data) as well as visual inspection of the
standard diagnostic plots. A statistically significant (P,0.05) improve-
ment in the comparison of nested models was defined as a decrease in
the objective function value of 3.84 U (for 1 degree of freedom). The
final population pharmacokineticmodelwas evaluated through visual pre-
dictive checks and bootstrap analysis.
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Monte Carlo simulation
Given the differences in treatment regimens in the healthy volunteer and
patient studies, the original data did not allow for direct comparison of the
time course of mefloquine between the two populations. To make this
comparison, the final population pharmacokinetic model was used to
simulate datasets for 1200 healthy volunteers and 1075 patients with
uncomplicated falciparum malaria (i.e. 25 complete datasets) after
administration of 8 mg/kg/day mefloquine for 3 days. Clinically relevant
parameters, half-life and T.MIC (MIC¼0.5 mg/L6), were then determined
for each population.
Results
Overall, 1470 plasmamefloquine concentration–time data points
from 24 healthy volunteers and 43 patients with P. falciparum
malaria were included in the population pharmacokinetic ana-
lysis. An additional 148 post-dose data points were excluded
from the dataset as concentrations were less than the limit of
quantification (107 samples for healthy volunteers and 41 sam-
ples for patients with malaria). A summary of the key study char-
acteristics is presented in Table 1 and population characteristics
(covariates) are summarized in Table 2.
A two-compartment model with a single transit compartment
and first-order elimination from the central compartment was
found to most adequately describe the mefloquine concentra-
tion–timedata. Themodel incorporated population parameter vari-
ability for CL/F, VC/F and KA; negligible variability was estimated for
CLD/F and VP/F and these were therefore fixed-effect parameters.
The population parameter variability for CL/F and VC/F comprised
between-occasion variability and between-subject variability,
Table 1. Key study characteristics
Population Study treatment Mefloquine dose Regimen
Number of
subjects
Number of
pharmacokinetic
samples
Healthy subjects fixed formulation 400 mg single dose 24 468
non-fixed formulation 500 mg single dose 508
Malaria patients fixed formulation 1200 mg split dose over 3 days (400+400+400 mg) 20 337
non-fixed formulation 25 mg/kg split dose over 2 days (15+10 mg/kg) 23 157
Total 67 1470
(a)
(b)
(c)
Figure 1. Schematic representation of clinical trial design for each study component. Dose administration time(s) are illustrated by black diamonds and
blood sampling timepoints are indicated by vertical lines. (a) Healthy volunteer study: randomized, crossover study designwith administration of a single
dose ofmefloquine (in combinationwith artesunate) in each study period (separate product in period 1 and then coformulated product in period 2 or vice
versa) with intensive blood sampling over the first 24 h followed by longitudinal sampling until 2160 h. (b) Patient study (coformulated product cohort):
randomized, parallel study design with administration of daily mefloquine (in combination with artesunate) for 3 days with intensive blood sampling
over the first 24 h followed by longitudinal sampling until 672 h. (c) Patient study (separate product cohort): randomized, parallel study design with
administration of daily mefloquine (in combination with artesunate) for 2 days with longitudinal blood sampling until 648 h.
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whereas the model could only account for between-occasion vari-
ability for KA with negligible between-subject variability. Combined
proportional and additive residual unexplained variability was sup-
ported by the model.
Examination of the association between estimates of pharma-
cokinetic parameters generated from the structural model and
covariates detected weight and the presence of malaria infection
as potential covariates for CL/F and VC/F. Introduction of covari-
ates into the structural model identified an effect of weight on
CL/F and weight and the presence of malaria infection on VC/F.
The inclusion of covariates substantially improved the model, in
particular the inclusion of the presence of malaria as a covariate
for VC/F, which resulted in a reduction in the variability in this par-
ameter and a 34 point reduction in the objective function value.
The population parameter estimates were CL/F¼1.22 L/h,
VC/F¼677 L, CLD/F¼1.34 L/h, VP/F¼186 L and KA¼0.985 h21,
with the presence of malaria infection associated with a 40%
reduction in VC/F. The final population pharmacokinetic model is
illustrated in Figure 2 and, based on the model diagnostics, was
found to well characterize the mefloquine concentration–time
data. Population parameter estimates of the final pharmacoki-
netic model are presented in Table 3. Median and 90% prediction
intervals obtained from 500 replicate datasets (bootstrap proced-
ure) were comparable to parameter estimates from the original
dataset, indicating the robustness and precision of the final popu-
lation pharmacokinetic model (Table 3).
The visual predictive check demonstrated agreement between
observed and simulated data, with the median and 90% predic-
tion intervals of mefloquine concentrations closely predicted over
the time course of the study for healthy volunteers administered
400 mg of mefloquine as a single dose and patients with malaria
administered 1200 mg of mefloquine as split doses over 2 or
3 days (Figure 3).
Full details of the model performance are available as
Supplementary data at JAC Online.
Output from the simulation of 1200 healthy subjects and 1075
malaria patients administered 8 mg/kg/daymefloquine for 3 days
is presented in Figure 4 and the determined pharmacokinetic
Table 2. Study population characteristics
Covariate Healthy subjects
Malaria patients
fixed formulation non-fixed formulation
Number of subjects 24 20 23
Age (years), mean+SD (range) 35.0+7.17 (20.9–47.8) 27.8+10.5 (18.0–50.3) 28.9+10.4 (16.4–45.5)
Body weight (kg), mean+SD (range) 55.9+10.4 (41.0–87.0) 50.4+6.42 (40.0–62.0) 50.7+6.49 (40.0–65.0)
Height (cm), mean+SD (range) 158+7.98 (145–180) 161+5.89 (150–170) 160+7.31 (147–174)
Gender 4 male/20 female 17 male/4 female 21 male/3 female
Treatment formulation 24 fixed/24 non-fixed 20 fixed/0 non-fixed 0 fixed/23 non-fixed
Presence of malaria infection 24 healthy/0 malaria 0 healthy/20 malaria 0 healthy/23 malaria
Baseline parasite count (number/mL), mean+SD (range) 0 28364+41663 (69–145860) 29330+45450 (20–140280)
Figure 2. Schematic of the final populationmodel describing the pharmacokinetics of mefloquine. ui, individual parameter; u, population parameter; hi,
randomeffect of between-subject variability; ki, randomeffect of between-occasion variability; CL/F, clearance; VC/F, volume of distribution of the central
compartment; CLD/F, intercompartmental clearance; VP/F, volume of distribution of the peripheral compartment; KA, absorption rate constant; WT, body
weight; PT, presence of malaria (where no malaria¼0 and malaria infection¼1); WTCL/F, effect of weight on clearance; WTVC/F, effect of weight on
central volume of distribution; PTVC/F, effect of the presence of malaria on central volume of distribution.
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parameters are presented in Table 4. Results indicate that patients
with uncomplicated P. falciparum malaria exhibit a 28% shorter
elimination half-life (407 h compared with 566 h) and a 14%
reduction in T.MIC (766 h compared with 893 h) compared with
healthy controls. Very similar results were obtained when simulat-
ing the separate product treatment regimen (15 mg/kg on day
1+10 mg/kg on day 2) (data not shown).
Discussion
The therapeutic effectiveness of long-acting antimalarials such as
mefloquine is dependent on themaintenance of drug levels above
the MIC until all parasites have been eliminated from the body
(with the contribution of the host’s immune system).6,8 Given
that underdosing would have significant implications for treat-
ment failure andmay contribute to the selection of drug-resistant
parasites, whereas overdosing could produce toxic side effects,
additional research is required to establish the appropriateness
of current dosing regimens.
The long elimination half-life of mefloquine is critical for treat-
ment efficacy.6,8 Previous research has noted considerable inter-
individual variability in this parameter;4,9–12 however, the factors
contributing to this variability have not been determined. Non-
compartmental pharmacokinetic analysis of the data utilized in
this study indicated a substantially lower elimination half-life of
mefloquine in patients with uncomplicated P. falciparum malaria
compared with healthy adult volunteers (294 h compared with
492 h, respectively).12 For the first time, to our knowledge, the
factors contributing to the variability in mefloquine pharmacokin-
etics between individuals have been investigated using a popula-
tion pharmacokinetic approach.
In this study, a two-compartment model with a single transit
compartment and first-order elimination from the central
compartment best characterized the mefloquine concentra-
tion–time data. Previously, limited population pharmacokinetic
analyses of mefloquine have been conducted and, for the most
part, these analyses utilized one-compartment models due to
sparse concentration–time data.6,16,17 On the other hand,
Charles et al.18 recently described two-compartment mefloquine
population pharmacokinetics in 1111 healthy military personnel
administered mefloquine for malaria prophylaxis. Similarly,
Svensson et al.19 described a two-compartment population phar-
macokinetic model of mefloquine enantiomers in patients with
falciparummalaria. Whilst there has been considerable variability
in pharmacokinetic values reported from both population and
traditional pharmacokinetic analyses, the population estimates
of apparent clearance and total volume of distribution reported
in the present study (1.22 L/h and 863 L, respectively) are consist-
ent with the low systemic clearance and large volume of distribu-
tion established for mefloquine.4
Not surprisingly, weight was identified as a significant covari-
ate for both the elimination and distribution of mefloquine. This
is in keeping with previously reported population pharmacokinetic
models that identified body weight as an important factor for
clearance16,17 and volume of distribution.17,19 However, for the
first time, this study was also able to demonstrate the
Table 3. Final model population parameter estimates of mefloquine pharmacokinetics and evaluation using bootstrap procedure (500 replicate
datasets)
Parameter Final model: estimate Bootstrap: median Bootstrap: %RSE Shrinkage Eta Bar P
Fixed effects
CL/F (L/h) 1.22 1.22 10.4
VC/F (L) 677 676 7.86
CLD/F (L/h) 1.34 1.33 14.4
VP/F (L) 186 189 7.46
KA (h
21) 0.985 0.990 8.00
WTCL/F 0.405 0.424 67.6
WTVC/F 0.828 0.820 32.7
PTVC/F 20.400 20.403 14.7
Random effects
BSV CL/F (%CV) 28.5 26.0 38.2 20.2% 0.818
BOV CL/F (%CV) 21.4 22.2 30.5 36.6%/62.4% 0.0982/0.0153
BSV VC/F (%CV) 1.85 1.96 274 98.2% 0.952
BOV VC/F (%CV) 36.5 35.8 10.2 0.190%/53.5% 0.322/0.0237
BOV KA (%CV) 60.2 59.7 15.1 10.5%/58.2% 0.483/0.139
Residual variability
proportional (%CV) 22.7 22.9 4.94 7.69%
additive (mg/L) 24.2 23.7 21.8 7.69%
CL/F, clearance; VC/F, volume of distribution of the central compartment; CLD/F, intercompartmental clearance; VP/F, volume of distribution of the
peripheral compartment; KA, absorption rate constant; WTCL/F, effect of weight on clearance; WTVC/F, effect of weight on central volume of
distribution; PTVC/F, effect of the presence of malaria infection on central volume of distribution; BSV, between-subject variability;
BOV, between-occasion variability; %RSE, relative standard error; %CV, coefficient of variation.
Refer to Figure 2 for structural representation of the final population pharmacokinetic model.
Reuter et al.
872
(a)
(b)
0
0 240 480 720 960 1200
Time (h)
1440 1680 1920 2160 2400
0 72 144 216 288 360 432
Time (h)
504 576 648 720 792 864 936
0 72 144 216 288 360 432 504 576 648 720 792 864 936
0
1
10
100
1000
10 000
1
10
100
1000
10 000
240 480 720 960 1200 1440 1680 1920 2160 2400
500
1000
Pl
as
m
a 
m
efl
oq
ui
ne
 c
on
ce
nt
ra
tio
n 
(µ
g/
L)
Pl
as
m
a 
m
efl
oq
ui
ne
 c
on
ce
nt
ra
tio
n 
(µ
g/
L)
1500
2000
0
6000
5000
4000
3000
2000
1000
2500
Figure 3. Visual predictive check of the median (continuous lines) and 90% prediction intervals (broken lines) for observed (grey) and simulated (black)
data with individual observed data (crosses). (a) Plasma concentration–time data for healthy volunteers administered a single oral dose of 400 mg of
mefloquine. (b) Plasma concentration–time data for patients with uncomplicated P. falciparum malaria administered 1200 mg of mefloquine as a split
dose over 2 days (720+480 mg). (c) Plasma concentration–time data for patients with uncomplicated P. falciparum malaria administered 1200 mg of
mefloquine as a split dose over 3 days (400+400+400 mg). For illustrative purposes, individual observed concentration data below the limit of
quantification of the assay have been designated a value of 2 mg/L in the graphical representation of data. The lower limit of quantification of the
assay (20 mg/L) is illustrated by the horizontal broken line.
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independent effect of the presence of malaria infection onmeflo-
quine disposition, with a 40% lower central volume of distribution
in patients compared with healthy adult subjects. Interestingly,
while there have been no previous population studies examining
mefloquine pharmacokinetics in bothmalaria patients and healthy
adults, analyses conducted by Ashley et al.16 and Simpson et al.6
reported body temperature as a significant covariate for volume
of distribution (with increasing temperature associated with
reduced volume). Body temperature could conceivably be seen
as a proxy for the presence ofmalaria infection, thereby supporting
our findings, although parasitaemia seems to be a better marker of
infection severity.
Results of the simulation of datasets for patients with malaria
and healthy adults administered 8 mg/kg/day mefloquine for
3 days indicated that the presence of malaria infection is asso-
ciated with a substantially lower half-life and a reduction in
T.MIC. Given that treatment effectiveness is characterized by the
maintenance of blood mefloquine concentrations above the MIC
for an adequate period of time to ensure maximum parasiticidal
activity, this shorter elimination phase and duration of action
could have implications for treatment outcomes. It should also
be noted that the MICmay vary with location and time and calcu-
lations should be adapted accordingly.
The physiological mechanism accounting for the differences in
mefloquine pharmacokinetics between malaria patients and
healthy adults is unknown. One possible explanation may be
due to differences in the plasma protein binding of mefloquine.
It has previously been established that mefloquine extensively
binds to plasma proteins, in particular acute-phase reactants
such as a1-acid glycoprotein (KA≈106 M21).20 Furthermore,
a1-acid glycoprotein levels have been shown to vary considerably
in certain diseases, including malaria with a reported 168%
increase in levels compared with healthy controls.21–23 This sub-
stantial increase in a1-acid glycoprotein levels in malaria would
theoretically result in increased mefloquine plasma protein bind-
ing and thus a reduction in the apparent volume of distribution.
Given that plasma a1-acid glycoprotein levels have also been
shown to vary in pregnancy, infancy and HIV infection as well as
states of malnutrition,21,22 the proposed relationship between
mefloquine pharmacokinetics and a1-acid glycoprotein is likely
to be an important factor in the determination of appropriate
treatment guidelines for these patients. Furthermore, as race/eth-
nicity have also been shown to influence a1-acid glycoprotein
levels,24 this may account, at least in part, for the considerable
variability in mefloquine pharmacokinetics reported in the litera-
ture. However, it should be noted that changes in protein binding
would also be expected to result in altered mefloquine clearance,
a result that was not observed in this study. Given that, for drugs
with a low hepatic extraction ratio, drug clearance is dependent
on both the fraction unbound and intrinsic clearance, it is conceiv-
able that the proposed increase in mefloquine protein binding in
patients with malaria may also be accompanied by an increase in
the intrinsic clearance of mefloquine, therefore resulting in no
observed changes inmefloquine clearance. An alternative explan-
ation is discussed below.
An important factor, which has not been investigated as part of
this study, is the chirality ofmefloquine. Mefloquine is administered
clinically as a racemicmixture of two enantiomers, (2)-mefloquine
and (+)-mefloquine, and therefore the stereoselective aspects of
the disposition and effects of mefloquine should be considered.
Previous research has demonstrated that the (2)-enantiomer
was associated with higher apparent volume of distribution and
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clearance values than the (+)-enantiomer.25,26 Studies have also
reported differences in the tissue and erythrocyte uptake of (+)-
and (2)-mefloquine aswell as stereoselective interaction ofmeflo-
quine enantiomers with P-glycoprotein.25,27–29 Consequently, it is
possible that the observed differences in the distribution of meflo-
quine between malaria patients and healthy controls in this study
may be explained by differences in the relative contribution of each
enantiomer to the overall pharmacokinetics of mefloquine.
Malaria infection is also associated with a number of phy-
siological changes that may affect mefloquine pharmacokinet-
ics, in particular changes in haematocrit caused by malaria
infection-induced haemolysis and/or altered haematopoiesis; in
fact, haematocrit levels for patients in this studywere, on average,
7% lower than those in healthy controls (data not shown). These
lower red blood cells levels would result in a reduction in the
uptake of mefloquine into the erythrocyte compartment, there-
fore increasing the free drug concentration in plasma and redu-
cing the volume of distribution. The adult malaria patients
enrolled in this study had no or mild anaemia; the contribution
of anaemia is expected to be much greater in chronically infected
African children.
It is most likely that the observed changes in mefloquine
pharmacokinetics in the presence ofmalaria infectionmaybe attrib-
utable to a combination of some or all of these factors. However, it is
important to note that this is further complicated by the time course
of the malaria infection after treatment with mefloquine, i.e. after
mefloquine treatment, the patient parasitic load decreases and
the physiological disturbances associated with malaria infection
progressively return to normal. Consequently, in these patients,
the early portion of the concentration–time profile is characterized
by ‘patient pharmacokinetics’ whereas the terminal phase would
be representative of the pharmacokinetics of mefloquine in
healthy volunteers. Given that the volume of distribution is dic-
tated by the early phase of the concentration–time profile and
clearance is more affected by the terminal phase, it is conceivable
that the physiological mechanisms proposed above (such as
changes in a1-acid glycoprotein levels and haematocrit) would
result in observed changes in the volume of distribution of meflo-
quine, but any changes in the clearance of the drug would not be
seen as the patients would have been ‘healthy’ by the end of the
study. In fact, whilsta1-acid glycoprotein levels were not available,
haematocrit values for the patients within this study progressively
increase throughout the treatment period and were equivalent to
those in healthy volunteers by day 28 (data not shown). Further
examination of the dynamic changes in these physiological pro-
cesses and their impact on the pharmacokinetics of mefloquine
and other drugs throughout the time course of malaria infection
is needed.
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Figure 4. Simulated plasma concentration–time data for healthy volunteers (n¼1200; grey line) and patientswith uncomplicated P. falciparum malaria
(n¼1075; black line) administered 8 mg/kg/day mefloquine for 3 days.
Table 4. Post hoc pharmacokinetic parameters from simulation of 1200
healthy volunteers and 1075 patients with uncomplicated P. falciparum
malaria administered 8 mg/kg/day mefloquine for 3 days
Parameter Healthy volunteers Malaria patients
CL/F (L/h) 1.16 (0.586–2.02) 1.14 (0.583–1.91)
VC/F (L) 598 (294–1053) 337 (169–582)
CLD/F (L/h) 1.34 1.34
VP/F (L) 186 186
KA (h
21) 1.18 (0.407–2.58) 1.21 (0.385–2.68)
t1
2A
(h) 66.8 (50.8–80.0) 52.8 (35.1–68.7)
t1
2B
(h) 566 (269–1050) 407 (219–705)
T.MIC (h) 893 (436–1575) 766 (362–1362)
CL/F, clearance; VC/F, volume of distribution of the central compartment;
CLD/F, intercompartmental clearance; VP/F, volume of distribution of the
peripheral compartment; KA, absorption rate constant; t12A, absorption
half-life; t1
2B
, elimination half-life; T.MIC, time above the MIC (500 mg/L).
Data are expressed as mean (5th–95th percentile interval).
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